Price
Target price
€11.40
€11.40
-4.200%
-0.5
-4.200%
€26.92
25.04.24 / Frankfurt
WKN: A1T7BJ / Symbol: ENTA / Name: Enanta / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Enanta Pharmaceuticals Inc. Stock
Heavy losses for Enanta Pharmaceuticals Inc. today as the stock fell by -€0.500 (-4.200%).
With 5 Buy predictions and 4 Sell predictions the community is currently undecided on Enanta Pharmaceuticals Inc..
Based on the current price of 11.4 € the target price of 26 € shows a potential of 128.07% for Enanta Pharmaceuticals Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Enanta Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | -4.200% | -2.459% | -7.031% | -62.342% | 35.227% | -71.531% | -84.794% |
| Ardelyx Inc. | -2.390% | -2.578% | -17.883% | 40.048% | 2.007% | -13.927% | - |
| Salarius Pharmaceuticals Inc. | 1.400% | -2.727% | -46.500% | -69.209% | -22.883% | -98.244% | -99.994% |
| Brainstorm Cell | 1.170% | 3.754% | -21.032% | -81.975% | 114.440% | -80.717% | - |
Comments
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JMP Securities from $42.00 to $23.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ENTA provided by MarketBeat